# Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)

> **NCT00334906** · PHASE4 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 75 (—)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** memantine HCl

## Key facts

- **NCT ID:** NCT00334906
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2007-11
- **Final completion:** —
- **Target enrollment:** 75 (—)
- **Last updated:** 2008-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00334906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00334906, "Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00334906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*